Biostar Pharmaceuticals Inc (BSPM) financial statements (2022 and earlier)

Company profile

Business Address NO. 588 SHIJI XI AVENUE
XIANYANG, SHAANXI PROVINCE, 712046
State of Incorp. MD
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments36540748417365920791
Cash and cash equivalents36540748417365920791
Receivables4613165,6947,0256,1917,82614,848
Inventory, net of allowances, customer advances and progress billings171167165167440317293
Inventory171167165167440317293
Prepaid expense0000   
Deposits current assets    0  
Other undisclosed current assets    233
Total current assets:9978916,3437,3657,2928,35315,236
Noncurrent Assets
Property, plant and equipment5,8465,8205,8175,8676,2706,4066,749
Intangible assets, net (including goodwill)5,3815,4215,4855,6076,0626,2856,741
Intangible assets, net (excluding goodwill)5,3815,4215,4855,6076,0626,2856,741
Deposits noncurrent assets26,57926,07121,31321,14815,67215,73016,207
Other undisclosed noncurrent assets2,6252,5752,5352,5155,2635,2825,442
Total noncurrent assets:40,43139,88635,15035,13733,26733,70335,139
TOTAL ASSETS:41,42740,77741,49342,50240,55942,05650,375
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,6862,7312,5282,8424,0983,8463,885
Accounts payable   2,8424,0983,8413,845
Taxes payable2,6862,7312,528  541
Debt2,4272,3812,3442,3262,4222,43120,000
Derivative instruments and hedges, liabilities166179439455131531
Other undisclosed current liabilities      (17,495)
Total current liabilities:5,2795,2915,3115,6236,5336,2926,421
Noncurrent Liabilities
Total liabilities:5,2795,2915,3115,6236,5336,2926,421
Stockholders' equity
Stockholders' equity attributable to parent, including:36,14835,48636,18236,87934,02735,76443,954
Common stock3333222
Additional paid in capital31,38231,38231,38231,38230,31730,31730,317
Accumulated other comprehensive income2,4031,6169986812,2822,4563,744
Retained earnings (accumulated deficit)(4,995)(4,870)(3,555)(2,541)(5,929)(4,365)2,537
Other undisclosed stockholders' equity attributable to parent7,3547,3547,3547,3547,3547,3547,354
Total stockholders' equity:36,14835,48636,18236,87934,02735,76443,954
TOTAL LIABILITIES AND EQUITY:41,42740,77741,49342,50240,55942,05650,375

Income statement (P&L) ($ in thousands)

9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
Revenues
(Revenue, Net)
   318645620802
Cost of revenue
(Cost of Goods and Services Sold)
   (355)(337)(321)(457)
Gross profit:   (37)308299345
Operating expenses(573)(1,528)(1,040)5,963(2,270)(7,159)(1,013)
Operating income (loss):(573)(1,528)(1,040)5,927(1,962)(6,860)(669)
Nonoperating income (expense)4482142611539816(10)
Other nonoperating income4820  502  
Interest and debt expense(47)(46)(46)(62)(105)(0)(38)
Other undisclosed income from continuing operations before equity method investments, income taxes47464662105038
Income (loss) from continuing operations before income taxes:(125)(1,314)(1,014)6,041(1,564)(6,844)(679)
Income tax expense (benefit)     (58)58
Other undisclosed loss from continuing operations   (2,653)   
Net income (loss) available to common stockholders, diluted:(125)(1,314)(1,014)3,388(1,564)(6,902)(620)

Comprehensive Income ($ in thousands)

9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
Net income (loss):(125)(1,314)(1,014)3,388(1,564)(6,902)(620)
Comprehensive income (loss):(125)(1,314)(1,014)3,388(1,564)(6,902)(620)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent787619317(1,602)(174)(1,287)309
Comprehensive income (loss), net of tax, attributable to parent:661(696)(697)1,786(1,738)(8,190)(311)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: